[go: up one dir, main page]

PE89199A1 - PHARMACEUTICAL COMPOSITION OF TIAZOLIDINADIONA AND AN ALPHA GLUCOSIDASE INHIBITOR FOR THE TREATMENT OF DIABETES - Google Patents

PHARMACEUTICAL COMPOSITION OF TIAZOLIDINADIONA AND AN ALPHA GLUCOSIDASE INHIBITOR FOR THE TREATMENT OF DIABETES

Info

Publication number
PE89199A1
PE89199A1 PE1998000536A PE00053698A PE89199A1 PE 89199 A1 PE89199 A1 PE 89199A1 PE 1998000536 A PE1998000536 A PE 1998000536A PE 00053698 A PE00053698 A PE 00053698A PE 89199 A1 PE89199 A1 PE 89199A1
Authority
PE
Peru
Prior art keywords
treatment
diabetes
tiazolidinadiona
pharmaceutical composition
glucosidase inhibitor
Prior art date
Application number
PE1998000536A
Other languages
Spanish (es)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en
Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE89199A1 publication Critical patent/PE89199A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

CARACTERIZADA PORQUE COMPRENDE a)UN SENSIBILIZADOR A INSULINA TAL COMO 5-[4-[2-(N-METIL-N-(2-PIRIDIL)AMINO)ETOXI]-BENCIL]TIAZOLIDINA-2,4-DIONA UTILIZANDOSE DE 2 mg A 12 mg, O TROGLITAZONA, CIGLITAZONA, PIOGLITAZONA, ENGLITAZONA Y b)UN AGENTE ANTIHIPERGLUCEMICO INHIBIDOR DE ALFA-GLUCOSIDASA TAL COMO ACARBOSA, EMIGLITATO O MIGLITOL. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DIABETES MELLITUS Y PARA LAS CONDICIONES ASOCIADAS A LA DIABETES MELLITUSCHARACTERIZED BECAUSE IT INCLUDES a) AN INSULIN SENSITIZER SUCH AS 5- [4- [2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI] -BENCIL] THIAZOLIDINE-2,4-DIONA USING 2 mg A 12 mg, OR TROGLITAZONA, CIGLITAZONA, PIOGLITAZONA, ENGLITAZONA AND b) AN ALPHA-GLUCOSIDASE ANTI-HYPERGLUCEMIC AGENT SUCH AS ACARBOSE, EMIGLITATE OR MIGLITOL. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF DIABETES MELLITUS AND FOR THE CONDITIONS ASSOCIATED WITH DIABETES MELLITUS

PE1998000536A 1997-06-18 1998-06-18 PHARMACEUTICAL COMPOSITION OF TIAZOLIDINADIONA AND AN ALPHA GLUCOSIDASE INHIBITOR FOR THE TREATMENT OF DIABETES PE89199A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712865.6A GB9712865D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806708.5A GB9806708D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
PE89199A1 true PE89199A1 (en) 1999-10-23

Family

ID=26311746

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000536A PE89199A1 (en) 1997-06-18 1998-06-18 PHARMACEUTICAL COMPOSITION OF TIAZOLIDINADIONA AND AN ALPHA GLUCOSIDASE INHIBITOR FOR THE TREATMENT OF DIABETES

Country Status (24)

Country Link
EP (1) EP0975343A1 (en)
JP (1) JP2001523271A (en)
KR (1) KR20010013845A (en)
CN (1) CN1274282A (en)
AP (1) AP9901720A0 (en)
AR (2) AR013352A1 (en)
AU (1) AU8799998A (en)
BG (1) BG103966A (en)
BR (1) BR9810186A (en)
CA (1) CA2294134A1 (en)
CO (1) CO4940453A1 (en)
DZ (1) DZ2519A1 (en)
EA (1) EA200000040A1 (en)
IL (1) IL133138A0 (en)
MA (1) MA26510A1 (en)
NO (1) NO996270L (en)
NZ (1) NZ501345A (en)
OA (1) OA11631A (en)
PE (1) PE89199A1 (en)
PL (1) PL337577A1 (en)
SK (1) SK179499A3 (en)
TR (1) TR199903072T2 (en)
UY (1) UY25051A1 (en)
WO (1) WO1998057635A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
BR0009934A (en) 1999-04-23 2002-06-04 Smithkline Beecham Plc Pharmaceutical
DE60233655D1 (en) 2001-04-04 2009-10-22 Ortho Mcneil Janssen Pharm R AND RETINOID X RECEPTOR MODULATORS
ES2321815T3 (en) 2001-04-04 2009-06-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. THERAPEUTIC COMBINATION THAT INCLUDES REABSORTION AND GLUCOSE INHIBITORS AND PPAR MODULATORS.
FR2832930A1 (en) * 2001-12-03 2003-06-06 Lipha PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES
JP2004067575A (en) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd Diabetes treatment effect enhancer
CN101121004B (en) * 2006-08-08 2010-07-21 鲁南制药集团股份有限公司 Medicine composition containing insulin intensifier and miglitol
CN101584688B (en) * 2008-05-24 2010-11-10 鲁南制药集团股份有限公司 Medicament composition for treating diabetes and complications of diabetes
CN101584705B (en) * 2008-05-24 2010-10-27 鲁南制药集团股份有限公司 A kind of pharmaceutical composition for treating diabetes and its complications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0601001B1 (en) * 1991-08-26 1997-04-16 PHARMACIA & UPJOHN COMPANY Liquid food product containing 3-guanidinopropionic acid
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
AR014881A1 (en) 2001-04-11
BR9810186A (en) 2000-08-08
IL133138A0 (en) 2001-03-19
DZ2519A1 (en) 2003-02-01
MA26510A1 (en) 2004-12-20
UY25051A1 (en) 2000-09-29
CO4940453A1 (en) 2000-07-24
CN1274282A (en) 2000-11-22
AR013352A1 (en) 2000-12-27
CA2294134A1 (en) 1998-12-23
WO1998057635A1 (en) 1998-12-23
NO996270D0 (en) 1999-12-17
PL337577A1 (en) 2000-08-28
AP9901720A0 (en) 1999-12-31
SK179499A3 (en) 2000-11-07
EP0975343A1 (en) 2000-02-02
BG103966A (en) 2000-07-31
NO996270L (en) 1999-12-17
OA11631A (en) 2004-11-22
EA200000040A1 (en) 2000-08-28
TR199903072T2 (en) 2000-07-21
AU8799998A (en) 1999-01-04
JP2001523271A (en) 2001-11-20
KR20010013845A (en) 2001-02-26
NZ501345A (en) 2001-10-26

Similar Documents

Publication Publication Date Title
PE83199A1 (en) PHARMACEUTICAL COMPOSITION OF TIAZOLIDINADIONA AND BIGUANIDE FOR THE TREATMENT OF DIABETES
TR200102874T2 (en) Biphenyl AP2 inhibitors and method with heterocyclic content.
PA8447401A1 (en) COMBINATIONS FOR SULFONILUREA DIABETES - GLITAZONE
PE99599A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
AR057970A2 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MELLITUS DIABETES AND CONDITIONS ASSOCIATED WITH MELLITUS DIABETES AND PROCEDURES TO PREPARE SUCH COMPOSITIONS
PE89199A1 (en) PHARMACEUTICAL COMPOSITION OF TIAZOLIDINADIONA AND AN ALPHA GLUCOSIDASE INHIBITOR FOR THE TREATMENT OF DIABETES
PE104499A1 (en) PHARMACEUTICAL COMPOSITION OF TIAZOLIDINDIONA AND INSULIN FOR THE TREATMENT OF DIABETES
PE99499A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
PE99799A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
PE108199A1 (en) PHARMACEUTICAL COMPOSITION OF TIAZOLIDINDIONA AND SULFONILUREA
UY26112A1 (en) 5- [4- [2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] THIAZOLIDINE-2,4-DIONA HYDROCHLORIDE
HK1041201A1 (en) Compatibility of beta agonists and antidiabetic agents
EA200300005A1 (en) SALT THIAZOLIDINDION FOR THE TREATMENT OF DIABETES MELLITUS
CY1107767T1 (en) THIAZOLIDINODIONI PRODUCER AND USE OF IT AS ANTIBIOTIC
BR0309375A (en) Treatment of metabolic syndrome
TR200000957T2 (en) The use of thiazolidinedione in the treatment of hyperglycemia
ECSP982541A (en) NEW METHOD OF TREATMENT II
ECSP982592A (en) NEW METHOD OF TREATMENT V
ECSP982535A (en) NEW TREATMENT METHOD (I)
ES2174748B1 (en) NEW SALT OF TIAZOLIDINDIONA AND ITS POLYMORPHES AS ANTI-DIABETIC AGENTS AND PROCEDURE FOR OBTAINING THEMSELVES.
ECSP982534A (en) NEW METHOD OF TREATMENT
ES2083319B1 (en) 5- (2- (4- (1,2-BENZISOTIAZOL-3-IL) -1-PIPERAZINYL) -Ethyl) -6-CHLORINE-1,3-DIHYDRO-2H-INDOL-2-ONA MONOHYDRATE.
UY26341A1 (en) METHOD FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETES.

Legal Events

Date Code Title Description
FC Refusal